REVIEW ARTICLE Sue Rimes, et al; ONCOLOGY Nurse Edition Vol. 25 No. 10 Patient education and counseling are essential in women at increased risk for ovarian and endometrial cancer. Women must be educated regarding the signs, symptoms, and risks associated with these cancers.
REVIEW ARTICLE John O. Schorge, et al; ONCOLOGY Vol. 25 No. 10 The timing and clinical benefit of a second debulking operation for recurrent disease is contentious. This article focuses on the recent debate regarding when—or whether—patients with ovarian cancer should undergo aggressive surgical resection.
NEWS & ANALYSIS Anna Azvolinsky, PhD Many doctors do not properly adhere to current guidelines for offering breast and ovarian cancer counseling and testing services to their female patients, according to a recent study from the Division of Cancer Prevention and Control at the CDC. The vignette-based national survey finds that while genetic counseling is recommended for women at high risk for breast and/or ovarian cancer, only 41% of physicians self-reported adhering to recommendations to refer for genetic counseling or testing.
REVIEW ARTICLE Maria Jose Echarri Gonzalez, et al;ONCOLOGY Vol. 25 No. 2 This article reviews the known data on the dose-effect relationship for platinum drugs in ovarian cancer, and explores why interest in platinum drugs has become the central focus of ovarian cancer treatment.
CME Patient education and counseling are essential in women at increased risk for ovarian and endometrial cancer. Women must be educated regarding the signs, symptoms, and risks associated with these cancers. •The Complexity of Hereditary Cancer Syndromes
Key points for primary care physicians from a new study: HIV-positive women are vulnerable to invasive cervical cancer. This finding underscores the need for screening per guidelines and to follow-up... More »
Women diagnosed with endometrial cancer at age 50 or younger had a fourfold increased risk for a subsequent colorectal cancer diagnosis, according to a historical cohort study published recently in... More »
Of the predominant gynecologic cancers, cancer of the uterine cervix is the least common, with only 12,200 new cases anticipated in the United States in 2010. Nevertheless, approximately 4,210 women... More »
Whole-pelvis intensity modulated radiotherapy has become a standard of care in cervical cancer, but efforts to find better and more specific ways to deliver interstitial brachytherapy are ongoing. More »
Some may argue that the new ACOG, ACS and other cervical cancer screening guidelines will detect the majority of at-risk women. We should not be content with settling for identifying a majority of... More »
A 43-year-old woman presented with symptoms of abdominal pain and uterine bleeding. At physical examination, a palpable mass was present in the right lower abdominal quadrant.
A 46-year-old woman presented for medical evaluation due to a 2-month history of increasing difficulty in ambulation, especially getting up out of a chair or climbing stairs. She had also noticed swelling and discoloration of both upper eyelids (as depicted).
A 48-year-old African American female presents with severe uterine bleeding. She states that she has been bleeding very heavily for the past two days and the flow is increasing. She is also diabetic and hypertensive. Pelvic examination revealed an enlarged irregularly shaped uterus. A large mass was noted by ultrasonography and the uterus was removed. A section of the mass is evaluated.
In this interview we discuss HPV-associated cancers, which are on the rise, and the low vaccination coverage for HPV with Edgar Simard, PhD, MPH, senior epidemiologist of surveillance research, who studies the impact of prevention and screening on cancer incidence at the American Cancer Society.
Primary Care Can't Thrive Without Nurse Practitioners Courtney H. Lyder, ND, May 17, 2013 With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
Emerging therapies in the management of ovarian cancer have resulted in a shift in paradigm, including in the appropriate time to institute therapy, and in the selection of therapy. This review focuses on chemotherapy and emerging biologic agents that present a therapeutic option for patients with recurrent ovarian cancer.
This article reviews the trials that have been conducted with PARP inhibitors in epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer, and places the impact of those results in the larger context of PARP inhibitor development.
The timing and clinical benefit of a second debulking operation for recurrent disease is contentious. This article focuses on the recent debate regarding when—or whether—patients with ovarian cancer should undergo aggressive surgical resection.
Epithelial ovarian cancer spreads prominently within the peritoneal cavity. In fact, we now know that high-grade serous cancers are often of tubal origin, and their presentation as tubo-ovarian masses renders it likely that IP spread occurs as an early event in their clinical evolution.
A 43-year-old woman presented with symptoms of abdominal pain and uterine bleeding. At physical examination, a palpable mass was present in the right lower abdominal quadrant.
A 46-year-old woman presented for medical evaluation due to a 2-month history of increasing difficulty in ambulation, especially getting up out of a chair or climbing stairs. She had also noticed swelling and discoloration of both upper eyelids (as depicted).
A 48-year-old African American female presents with severe uterine bleeding. She states that she has been bleeding very heavily for the past two days and the flow is increasing. She is also diabetic and hypertensive. Pelvic examination revealed an enlarged irregularly shaped uterus. A large mass was noted by ultrasonography and the uterus was removed. A section of the mass is evaluated.
In this interview we discuss HPV-associated cancers, which are on the rise, and the low vaccination coverage for HPV with Edgar Simard, PhD, MPH, senior epidemiologist of surveillance research, who studies the impact of prevention and screening on cancer incidence at the American Cancer Society.
